Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Return on Capital Employed data on file, last reported at 315.56% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 315.56%, down 18384.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 315.56% (down 18384.0% YoY), and the FY2025 annual result was 928.76%, down 78963.0% from the prior year.
• Return on Capital Employed eased to 315.56% in Q1 2026 per VVOS's latest filing, from 271.77% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 29.58% in Q1 2022 and troughed at 534.7% in Q4 2023.
• A 5-year average of 223.93% and a median of 187.94% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 32831 bps in 2023, then surged 42663 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 271.15% in 2022, then slumped by 97 bps to 534.7% in 2023, then surged by 80 bps to 108.07% in 2024, then tumbled by 151 bps to 271.77% in 2025, then slipped by 16 bps to 315.56% in 2026.
• Business Quant data shows VVOS's Return on Capital Employed at 315.56% in Q1 2026, 271.77% in Q4 2025, and 88.7% in Q3 2025.